Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK-4082 Formulation 1 (F1), MK-4082 Formulation 1, MK-4082 Formulation 2 (F2), MK-4082 Formulation 2, MK-4082 Formulation 4 (F4), MK-4082 Formulation 4
MK-4082 · 2 trials · 1 indication
Blood samples will be collected to determine the AUC0-∞ of MK-4082.
Blood samples will be collected to determine the Cmax of MK-4082.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
| Arm | Type | Description |
|---|---|---|
| MK-4082 | EXPERIMENTAL | Participants will move sequentially through 2 periods in Part 1. In Period 1, participants will receive a single oral dose of MK-4082 on Day 1. In Period 2, participants will receive a single oral dose of MK-4082 on Day 1 plus oral diltiazem for multiple days. In Part 2 participants receive a single dose of MK-4082 or placebo. |
| Panel A: Dose Escalation to Dosage 1 | EXPERIMENTAL | Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 1. |
| Panel B: Dose Escalation to Dosage 2 | EXPERIMENTAL | Participants receive escalating doses of oral MK-4082 QD or a dose-matched placebo to reach maintenance dose 2. |
| Panel C: Dose Escalation to Dosage 3 | EXPERIMENTAL | Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 3. |
| Panel D: Dose Escalation to Dosage 4 | EXPERIMENTAL | Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 4. |
| Panel E: Dose Escalation to Dosage 5 | EXPERIMENTAL | Participants receive escalating doses of oral MK-4082 once daily (QD) or a dose-matched placebo to reach maintenance dose 5. |
| Name | Type | Description |
|---|---|---|
| MK-4082 | DRUG | Oral administration |
| Diltiazem | DRUG | Oral administration |
| Rescue medication | DRUG | All participants will receive ondansetron as a rescue medication. Ondansetron is a medication used to prevent nausea or vomiting. |
| Placebo | DRUG | Oral Tablet |
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Body mass index (BMI) between 18 and 32 kg/m\^2, inclusive Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of previou...
MK-4082 is an investigational small molecule being studied in healthy participants, including healthy overweight participants, in early-stage clinical trials. It is not approved for any condition and is currently in Phase 1 clinical development.
MK-4082 targets the GLP-1 receptor. It is a small molecule designed to interact with this receptor, which is involved in metabolic regulation. The drug is being evaluated in healthy participants in Phase 1 trials.
MK-4082 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy participants.
MK-4082 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials are ongoing, one active but not recruiting and one currently recruiting participants.
MK-4082 is being studied in two Phase 1 trials. NCT07388667 is a study in healthy overweight participants with 120 enrolled, active but not recruiting. NCT07697625 is a trial in healthy participants with 28 enrolled, currently recruiting. Both are conducted in the United States.
Yes, MK-4082 is also known as MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), and MK-4082 Formulation 4 (F4). These names refer to different formulations of the same investigational drug being tested in clinical trials.